Recombinant factor VII (Activated) for haemorrhagic complications of severe sepsis treated with recombinant protein C (activated)

Acta Haematologica

Volumn 116, Issue 2, 2006, Pages 126-130

  Michalska Krzanowska, Grazyna ^a   Czupryńska, Maria ^b  

^a Clinical Hospital No 2   (Poland)

^b M Curie Hospital   (Poland)

Author keywords

Activated protein C; Recombinant factor VIIa; Sepsis; Septic shock

Indexed keywords

CYCLOSPORIN; DROTRECOGIN; OMEPRAZOLE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; STEROID;

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CASE REPORT; CAUSE OF DEATH; CHOLECYSTECTOMY; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; KIDNEY TRANSPLANTATION; LAPAROTOMY; NEPHRECTOMY; PERIOPERATIVE PERIOD; PERITONITIS; PEROPERATIVE CARE; PRIORITY JOURNAL; PYELONEPHRITIS; SEPSIS; SEPTIC SHOCK; SYMPTOM; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

ADULT; FACTOR VIIA; FACTOR VIII; FEMALE; HEMORRHAGE; HUMANS; MIDDLE AGED; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 33747382816     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093643     Document Type: Article

References (15)

1. Friedman G, Silva E, Vincent JL: Has the mortality of septic shock changed with time? Crit Care Med 1998;26:2078-2086.
2. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002;296:1880-1882.
3. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnel BW: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:1199-11203.
4. Dhainaut JF, Laterrre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Uterback BG: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003;29:894-903.
5. Bernard G, Vincent JL, Laterre PF, La Rosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Warren BL, Eid A, Singer P, Oillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kübler A, Knaub S, Keinecke HO, Heinrrichs H, Schindel F, Juers M, Bone RC, Opal SM: Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-1878.
7. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925.
8. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L: Effects of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000;11:121-125.
9. Hendricks HGD, Meijer K, Wolf J: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001;71:402-407.
10. Ziȩtkiewicz M, Garlicki M, Domagała J: Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002;123:384-386.
11. Michalska-Krzanowska G, Sajdak R, Stasiak-Pikuła E: Zastosowanie preparatu rekombinowanego czynnika VIIa w leczeniu krwotoku pooperacyjnego w oddziale intensywnej terapii (Use of recombinant factor VIIa to treatment postoperative bleeding in ITU). Anestezjol Intensywna Ter 2002;34:24-26.
12. Michalska-Krzanowska G, Stasiak-Pikuła E, Sajdak R: Efekt zastosowania preparatu rekombinowanego czynnika VIIa w krwotoku okołooperacyjnym podczas resekcji guza nerki (Effects of recombinant factor VIIa in bleeding during kidney tumor resection). Urol Polska 2001,54:4-6.
13. Michalska-Krzanowska G, Sajdak R, Stasiak-Pikuła E: Effects of recombinant factor VIIa in haemorrhagic complications of urological operations. Acta Haematol 2003,109:158-160.
14. Kenet G, Walden R, Eldad A: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
15. Martinovitz U: The use of rFVIIa as an adjunct treatment for hemorrhage control in trauma and surgery. Bloodline Rev 2001;1:9-11.